Literature DB >> 26670077

Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma.

Chihiro Dohi1, Kazuhiro Nouso1,2, Koji Miyahara1, Yuki Morimoto1, Nozomu Wada1, Hideaki Kinugasa1, Yasuto Takeuchi1, Kenji Kuwaki1, Hideki Onishi1, Fusao Ikeda1, Shinichiro Nakamura1, Hidenori Shiraha1, Akinobu Takaki1, Hiroyuki Okada1.   

Abstract

AIM: Recurrence of hepatocellular carcinoma (HCC) is observed frequently, even after curative treatments. The aim of this study is to elucidate the risk factors for recurrence of HCC after radiofrequency ablation (RFA), focusing on the carcinogenic potential of the liver assessed by α-fetoprotein (AFP).
METHODS: We enrolled 357 consecutive patients who underwent complete ablation by RFA for primary HCC (≤3 cm, ≤3 tumors) and analyzed the correlation between 17 critical parameters, including AFP and HCC recurrence.
RESULTS: Recurrence was observed in 236 patients during a mean observation period of 54.3 months. Multivariate analysis revealed that multiple tumors (risk ratio [RR] = 1.70, 95% confidence interval [CI] = 1.27-2.26, P < 0.001), high AFP (>10 ng/mL, RR = 1.45, 95% CI = 1.09-1.94, P < 0.001) and high des-γ-carboxyprothrombin (>40 mAU/mL, RR = 1.52, 95% CI = 1.13-2.02, P < 0.005) were significantly correlated with recurrence. AFP was selected as a significant factor even when the cut-off level was set lower (≤5 ng/mL). The risk of recurrence increased linearly according to the increase of the lowest AFP level after RFA and the adjusted ratios relative to AFP less than 5 ng/mL were 1.56, 2.14, 2.57 and 3.13 in AFP 5-10 ng/mL, 10-20 ng/mL, 20-50 ng/mL and over 50 ng/mL, respectively. In addition, the recurrence rate was predicted by the AFP level after RFA, regardless of the level before the treatment.
CONCLUSION: AFP less than 5 ng/mL after curative RFA was an important predictor of a better prognosis and was considered to indicate the low carcinogenic potential of the non-cancerous liver.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  alpha-fetoprotein; hepatocellular carcinoma recurrence; radiofrequency ablation

Year:  2016        PMID: 26670077     DOI: 10.1111/hepr.12636

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

2.  Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma.

Authors:  Nobuharu Tamaki; Atsushi Kuno; Atsushi Matsuda; Hanako Tsujikawa; Ken Yamazaki; Yutaka Yasui; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Masaaki Korenaga; Masashi Mizokami; Masayuki Kurosaki; Michiie Sakamoto; Hisashi Narimatsu; Namiki Izumi
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

3.  Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.

Authors:  Andrea Casadei Gardini; Giorgia Marisi; Matteo Canale; Francesco Giuseppe Foschi; Gabriele Donati; Giorgio Ercolani; Martina Valgiusti; Alessandro Passardi; Giovanni Luca Frassineti; Emanuela Scarpi
Journal:  Onco Targets Ther       Date:  2018-10-05       Impact factor: 4.147

4.  Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Pei-Chang Lee; Yi-You Chiou; Nai-Chi Chiu; Ping-Hsien Chen; Chien-An Liu; Wei-Yu Kao; Teh-Ia Huo; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin; Jaw-Ching Wu; Chien-Wei Su
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

5.  Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: Evidence from a meta-analysis.

Authors:  Yue Chang; Baiqing Liu; Haiyan Niu; Zhenguo Wang; Shihai Xia; Hai Li
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.